Cencora heads into its May 6 quarterly report with short sellers pulling back and the options market showing little urgency — a setup that looks more relaxed than charged.
The most telling move in the data is what shorts have done this week. Short interest fell roughly 6.3% over seven days, dropping from around 5.1 million shares to just under 4.8 million. That brings SI % FF to 2.5% — a low level for any large-cap healthcare name and well below the April highs. The retreat is deliberate: shorts added through most of April before cutting exposure sharply on April 23, suggesting the earlier build was tactical rather than structural conviction. The lending market confirms the benign picture. Availability is extremely loose — less than 1.4% of the borrowable pool is currently in use, a fraction of the 52-week peak of 5.4%. Cost to borrow has edged up about 12% over the week to 0.47%, but in absolute terms that is barely above zero. None of the lending signals point to a squeeze or a crowding dynamic.
Options traders are equally calm. The put/call ratio has drifted to 0.61, fractionally below its 20-day mean of 0.61 and running near the lower end of the past year's range — the 52-week low is 0.54, the high 0.97. There is no elevated demand for downside protection into the print. The z-score sits just below zero, meaning options positioning is if anything slightly more bullish than the recent average. Taken together, the borrow and options data describe a market that is comfortable — not braced — ahead of earnings.
The Street's message is broadly constructive, though a few cracks appeared this month. Evercore ISI lowered its target to $360 from $420 on April 8, keeping an Outperform but signalling less conviction on the near-term path. William Blair initiated coverage this week at Market Perform, adding a cautious voice without a price target. That contrasts with the tone from February, when JPMorgan, Wells Fargo, and Barclays all lifted targets into the $400–430 range after the last results, and Morgan Stanley upgraded to Overweight ahead of that print. At $312 now, the stock has given back meaningful ground since those raises. The current P/E of 17.1x and EV/EBITDA of 12.1x sit at levels that are not demanding for a business of this quality, though both are modestly higher than a month ago. The 12-month forward EPS growth estimate scores in the 76th percentile of the universe — a healthy reading that likely underpins the majority of the bullish targets still on the books.
One nuance in the institutional picture is worth noting. T. Rowe Price added 3.4 million shares in the quarter to March 31 — a substantial increment that represents meaningful incremental conviction from one of the stock's largest active holders. JPMorgan Asset Management added 748,000 shares in the same period. FMR (Fidelity) added 1.6 million. Against that, the insider register shows the CEO and CFO selling shares in February and March at prices in the $350–360 range — higher than where the stock trades today. Those were largely award-related sales, but the direction of travel at the executive level has been consistent outflows over the rolling 90-day window, with a net of around 67,000 shares changing hands at an aggregate value above $23 million.
Earnings history reinforces a pattern worth filing away. The last two prints each produced a day-one decline of around 2.65%, with one recovering into positive territory over the following week and the other extending lower. The consistency of the initial dip — almost exactly the same magnitude on both occasions — sets an informal baseline for what the market has priced in as its reflexive response. May 6 will show whether that pattern holds or whether the quieter short positioning and relaxed options market reflect a more balanced expectations set this time around.
See the live data behind this article on ORTEX.
Open COR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
